This Thursday, Feb. 28, 2013, photo shows specialist Fabian Caceres works at his post on the floor of the New York Stock Exchange. The stock market pushed higher Thursday afternoon, sending the Dow tantalizingly close to a record high. (AP Photo/Richard Drew)
Flamel shares rise after lawsuit tossed out
Published: 05:47:33 PM, Fri 22 March 2013 UTC
NEW YORK (AP) — Shares of Flamel Technologies SA rose Friday on news that a judge dismissed a class action suit against the French pharmaceutical company.
Flamel said a U.S. District Court judge in New York issued a summary judgment on March 8, throwing out the lawsuit against the company and its former CEO.
The company, based in Lyon, France, develops and makes specialty drugs. The lawsuit was first filed in 2007, according to a statement from Flamel. The suit argued that Flamel broke securities rules and made false claims about its treatment for heart failure and high blood pressure, Coreg CR. The plaintiffs said the misleading statements artificially inflated the company's stock price.
Flamel rose 11 cents, or 2.5 percent, to $4.41 in afternoon trading. Its American depositary shares have traded between $2.85 and $5.78 over the past 52 weeks.
Tags:
ap, lyon, law_crime, cents, judgment, civil procedure, news, percent, afternoon trading, friday, ceo, stock, plaintiffs, stock price, lawsuit, stock market, new york, high blood pressure, hypertension, heart failure, class action, false claims, plaintiff, jurisdiction, district court judge, class action suit, american depositary shares, summary judgment, specialty drugs, flamel, flamel technologies sa, flamel shares, misleading statements artificially inflated the, french pharmaceutical company, coreg cr, securities rules
